118 related articles for article (PubMed ID: 17183755)
1. Integrative tumor board: metastatic breast cancer.
Koch A; Ellis J; Gyllenhaal C; Tripathy D; Lo C; Oberbaum M; Samuels N; Singer SR; Gupta G; Block KI
Integr Cancer Ther; 2006 Dec; 5(4):373-90. PubMed ID: 17183755
[No Abstract] [Full Text] [Related]
2. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
Karachaliou N; Saloustros E; Vamvakas L; Mavroudis D; Georgoulias V
Ann Oncol; 2010 Aug; 21(8):1729-1730. PubMed ID: 20601370
[No Abstract] [Full Text] [Related]
3. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
Miller KD
Clin Breast Cancer; 2003 Feb; 3(6):421-2. PubMed ID: 12636887
[No Abstract] [Full Text] [Related]
4. [A case of a patient with a triple negative breast cancer and complete response of lung, mediastinal and skeletal metastases after treatment with paclitaxel and bevacizumab].
Bravencová Z
Klin Onkol; 2010; 23(5):358-60. PubMed ID: 21061684
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and breast cancer: the E2100 outlier.
Fojo T; Wilkerson J
Lancet Oncol; 2010 Dec; 11(12):1117-9. PubMed ID: 21126685
[No Abstract] [Full Text] [Related]
6. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
Kikuchi Y; Takano M; Kudoh K; Kita T; Sato K
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):189-91. PubMed ID: 18778887
[No Abstract] [Full Text] [Related]
8. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
9. Unresectable angiosarcoma treated with bevacizumab and paclitaxel.
Nespereira-Jato MV; Peña-Panabad C; Quindós-Varela M; García-Silva J
Actas Dermosifiliogr; 2014 Jun; 105(5):520-2. PubMed ID: 24144236
[No Abstract] [Full Text] [Related]
10. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
11. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.
Rahman HT; Yeh S; Bergstrom CS
J Ocul Pharmacol Ther; 2013 Apr; 29(3):360-2. PubMed ID: 23061416
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
13. The breast cancer panel: a case-based discussion on the use of targeted therapies for primary and metastatic disease.
Fortenbaugh C
ONS News; 2006; 21(8 Suppl):37-8. PubMed ID: 16925144
[No Abstract] [Full Text] [Related]
14. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
Miller KD
Breast Cancer Res; 2004; 6(3):128-32. PubMed ID: 15084233
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus bevacizumab for metastatic breast cancer.
Rossi A; Torri V; Gridelli C
N Engl J Med; 2008 Apr; 358(15):1637; author reply 1637-8. PubMed ID: 18411431
[No Abstract] [Full Text] [Related]
16. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Farhat MH; El-Saghir NS; Shamseddine AI
Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.
Ranade AA; Bapsy PP; Nag S; Raghunadharao D; Raina V; Advani SH; Patil S; Maru A; Gangadharan VP; Goswami C; Sekhon JS; Sambasivaiah K; Parikh P; Bakshi A; Mohapatra R
Asia Pac J Clin Oncol; 2013 Jun; 9(2):176-81. PubMed ID: 23176568
[TBL] [Abstract][Full Text] [Related]
18. Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer.
Wilson TJ; Heth JA
J Clin Neurosci; 2012 Mar; 19(3):468-9. PubMed ID: 22245272
[TBL] [Abstract][Full Text] [Related]
19. [Adjuvant chemotherapy for breast cancer and targeted therapies].
Dufresne A; Bachelot T; Blay JY
Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
[No Abstract] [Full Text] [Related]
20. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
